Back to Search
Start Over
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
- Source :
- The Lancet Gastroenterology & Hepatology; October 2021, Vol. 6 Issue: 10 p803-815, 13p
- Publication Year :
- 2021
-
Abstract
- Treatment options are sparse for patients with advanced cholangiocarcinoma after progression on first-line gemcitabine-based therapy. FGFR2fusions or rearrangements occur in 10–16% of patients with intrahepatic cholangiocarcinoma. Infigratinib is a selective, ATP-competitive inhibitor of fibroblast growth factor receptors. We aimed to evaluate the antitumour activity of infigratinib in patients with locally advanced or metastatic cholangiocarcinoma, FGFR2alterations, and previous gemcitabine-based treatment.
Details
- Language :
- English
- ISSN :
- 24681253
- Volume :
- 6
- Issue :
- 10
- Database :
- Supplemental Index
- Journal :
- The Lancet Gastroenterology & Hepatology
- Publication Type :
- Periodical
- Accession number :
- ejs57705554
- Full Text :
- https://doi.org/10.1016/S2468-1253(21)00196-5